Monday, October 15, 2012
Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., said updated data from its Phase II trial of oral sapacitabine in older patients with intermediate-2 or high-risk myelodysplastic syndromes after treatment failure with front-line hypomethylating agents such as Vidaza (azacitadine, Celgene Corp.) and/or Dacogen (decitabine, Astex Pharmaceuticals Inc.) showed a median overall survival rate to date for all 63 patients of 252 days, or about eight months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.